← Back to Analyst Consensus 
GLUE Buy
Monte Rosa Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 15
30-Day Momentum
▲ 1 upgrades / ▼ 0 downgrades / 1 reiterations from 1 firms
Next Earnings
Nov 5, 2026 (10 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 5, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Oct 1, 2026 | HC Wainwright & Co. | initiate | — → Buy | — | 44% |
| Sep 9, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| Aug 25, 2026 | Guggenheim | reiterate | Buy → Buy | — | 52% |
| Aug 7, 2026 | JP Morgan | maintain | Overweight → Overweight | — | 55% |
| Aug 7, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Aug 7, 2026 | Wells Fargo | maintain | Overweight → Overweight | — | 54% |
| Aug 3, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Jun 30, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| May 11, 2026 | JP Morgan | maintain | Overweight → Overweight | — | 55% |
| Mar 18, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Mar 18, 2026 | Wells Fargo | maintain | Overweight → Overweight | — | 54% |
| Jan 14, 2026 | Piper Sandler | reiterate | Overweight → Overweight | $37 | 54% |
| Jan 8, 2026 | Wells Fargo | maintain | Overweight → Overweight | $30 | 54% |
| Jan 8, 2026 | Guggenheim | maintain | Buy → Buy | $34 | 52% |
| Dec 16, 2025 | Wells Fargo | upgrade | Equal-Weight → Overweight | $22 | 54% |
| Nov 7, 2025 | Wells Fargo | maintain | Equal-Weight → Equal-Weight | $13 | 54% |
| Mar 21, 2025 | Wells Fargo | maintain | Equal-Weight → Equal-Weight | $10 | 54% |
| Mar 21, 2025 | Wedbush | maintain | Outperform → Outperform | $17 | 58% |
| Mar 12, 2025 | LifeSci Capital | initiate | — → Outperform | $19 | 57% |
| Dec 19, 2024 | Wells Fargo | downgrade | Overweight → Equal-Weight | $11 | 54% |
| Sep 12, 2024 | Wedbush | reiterate | Outperform → Outperform | $11 | 58% |
| Aug 12, 2024 | Wells Fargo | maintain | Overweight → Overweight | $17 | 54% |
| Jun 28, 2024 | Piper Sandler | reiterate | Overweight → Overweight | $16 | 54% |
| May 22, 2024 | Wedbush | reiterate | Outperform → Outperform | $11 | 58% |
| Feb 15, 2024 | Wedbush | initiate | — → Outperform | $11 | 58% |
| Oct 19, 2023 | JP Morgan | maintain | Overweight → Overweight | $11 | 55% |
| Aug 11, 2023 | Credit Suisse | reiterate | Neutral → Neutral | $11 | — |
| May 12, 2023 | Credit Suisse | reiterate | Neutral → Neutral | $11 | — |
| Mar 17, 2023 | Credit Suisse | maintain | — → Neutral | $11 | — |
| Jan 3, 2023 | Wells Fargo | upgrade | Equal-Weight → Overweight | $19 | 54% |
| Oct 13, 2022 | UBS | initiate | — → Buy | $22 | 54% |
| Aug 15, 2022 | Jefferies | initiate | — → Buy | $20 | 52% |
| May 12, 2022 | Piper Sandler | maintain | — → Overweight | $21 | 54% |
| Apr 28, 2022 | Credit Suisse | initiate | — → Neutral | $19 | — |
| Feb 10, 2022 | Wells Fargo | initiate | — → Equal-Weight | $19 | 54% |
| Oct 14, 2021 | SVB Leerink | initiate | — → Market Perform | $20 | — |
| Jul 19, 2021 | Guggenheim | initiate | — → Buy | $30 | 52% |
| Jul 19, 2021 | Piper Sandler | initiate | — → Overweight | $40 | 54% |
| Jul 19, 2021 | JP Morgan | initiate | — → Overweight | $38 | 55% |
Price Target Trend
May 28, 2026 Oct 26, 2026
EPS Estimates
0y —
+1q —
+1y —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days